Canakinumab MAP in COVID-19 Pneumonia With CRS

Sponsor
Novartis Pharmaceuticals
Study ID
NCT04476706
Status
No Longer Available

Conditions

  • Cytokine Release Syndrome in COVID-19-induced Pneumonia

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a global Managed Access Program (MAP) to provide access to canakinumab to patients with cytokine release syndrome resulting from COVID-19 pneumonia

Key Dates

Status verified
Jan 2021